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A b s t r a c t
Background: Due to the myopathic adverse events of statins, safer alternatives are being studied. Bempedoic acid (ETC-1002) 
is a novel low-density lipoprotein cholesterol (LDL-C)-lowering agent, currently under trial in hypercholesterolaemic patients. 
Aim: To investigate the tolerability and efficacy of ETC-1002 in hypercholesterolaemic patients through a systematic review 
of published randomised controlled trials (RCTs).
Methods: Five databases were searched for RCTs that investigated the safety and efficacy of ETC-1002 in hypercholesterol-
aemic patients. The retrieved search results were screened, and then data were extracted and analysed (as mean difference 
[MD] or odds ratio [OR]) using the RevMan software.
Results: Five RCTs (625 hypercholesterolaemic patients) were identified. ETC-1002 was superior to placebo in terms of percent-
age changes from baseline in serum levels of LDL-C (MD –26.58, 95% confidence interval [CI] –35.50 to –17.66, p < 0.0001), 
non–high-density lipoprotein cholesterol (MD –21.54, 95% CI –28.48 to –14.6, p < 0.00001), and apolipoprotein-B (MD 
–15.97, 95% CI –19.36 to –12.57, p < 0.0001). When compared to ezetimibe, ETC-1002 was superior in reducing LDL-C 
(–30.1 ± 1.3 vs. –21.1 ± 1.3). Regarding safety, ETC-1002 did not increase the risk of all adverse events (OR 0.58, 95% CI 
0.37–0.91, p = 0.02) and arthralgia (OR 0.32, 95% CI 0.13–0.81, p = 0.02) compared to placebo. All other adverse events 
including myalgia, headache, and urinary tract infections were similar between ETC-1002 and placebo groups. The evidence 
certainty in the assessed outcomes was moderate to high except for lipoprotein(a), free fatty acids, and very low-density 
lipoprotein particle number (very low certainty).
Conclusions: ETC-1002 is a safe and effective lipid-lowering agent and may be a suitable alternative in statin-intolerant pa-
tients. Well-designed studies are needed to explore the long-term safety and efficacy of ETC-1002 in these patients.
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INTRODUCTION
Cardiovascular disease (CVD) remains the leading cause of 
death worldwide, and its prevalence is expected to rise by 
approximately 10% in 2030 [1, 2]. A cost prediction study 
by the American Heart Association (AHA) anticipated the 
direct medical costs (measured in 2008 dollars) of CVD to 
triple by 2030 [1]. Therefore, improvements in treatment and 
protection from the established risk factors are warranted to 
minimise the growing burden of CVD [1].
Statins are the standard of care for prevention of car-
diovascular events, supported by a large body of evidence 
showing their effectiveness in reducing low-density lipopro-
tein cholesterol (LDL-C) levels [3]. However, statin therapy 
is associated with muscular adverse events in 5% to 29% 
of patients [4–7], referred to as statin intolerance. Although 
there is no universal definition of statin intolerance, muscular 
symptoms including pain, myalgia, and rarely life-threatening 
rhabdomyolysis were reported in several studies [4, 7, 8]. 
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Conversely, cessation of statin therapy significantly increases 
the cardiovascular risk and reduces the lifespan by an average 
of eight years [8, 9]. There is an imperative need for treat-
ment alternative to statins in order to improve cardiovascular 
outcomes in patients with hypercholesterolaemia. This was 
recognised in the latest guidelines of the American College 
of Cardiology/AHA [10] and the European Atherosclerosis 
Society Consensus Panel statement on statin-associated 
muscle symptoms [4]. 
Bempedoic acid (ETC-1002, Esperion Therapeutics Inc., 
Ann Arbor, MI, USA) is a novel investigational drug for dys-
lipidaemia. It inhibits adenosine triphosphate citrate lyase (an 
enzyme upstream of 3-hydroxy-3-methylglutaryl-coenzyme 
A reductase) to reduce cholesterol biosynthesis [11, 12]. 
Preclinical studies have shown promising inhibitory effects on 
sterol and fatty acid biosynthesis. In addition, ETC-1002 could 
enhance fatty acid oxidation in animal models [11–14]. 
Supported by the favourable effects in preclinical and early 
phase I studies, a range of doses have been investigated in 
several trials that showed good tolerability for this agent with 
no dose-limiting adverse effects [15–18]. 
In this study, we aimed to systematically review the 
published randomised controlled trials (RCTs) on the safety 
and efficacy of ETC-1002 in hypercholesterolaemic patients.
METHODS
This review was conducted and reported according to the 
preferred reporting items for systematic reviews and me-
ta-analyses (PRISMA) statement (Suppl. Fig. 1 — see journal 
website). The protocol of this study was predefined and is 
available as Supplementary Figure 2 (see journal website).
Eligibility criteria
We included RCTs that fulfilled the following criteria; 
(1) population: hypercholesterolaemic men and women 
aged 18 to 80 years, (2) intervention: ETC-1002 at all doses, 
(3) control: any other agent with head-to-head comparison, 
and (4) outcomes: safety and efficacy parameters related to 
the treatment. The primary efficacy outcomes were LDL-C, 
high-density lipoprotein cholesterol (HDL-C), non-HDL-C, 
and total cholesterol levels. The primary safety outcomes were 
all adverse events, serious adverse events, adverse events lead-
ing to discontinuation, headache, and myalgia. We excluded 
the following types of studies; (1) non-randomised trials, (2) 
non-English publications, and (3) theses or (4) conference pa-
pers due to inadequate data for risk of bias (ROB) assessment. 
Search strategy
Five electronic databases were searched on 23rd May 2018 for 
relevant articles: Scopus, Cochrane Central, PubMed, Em-
base, and Web of Science. The following terms were used: 
(bempedoic acid OR ETC-1002 OR ESP55016) AND (familial 
hypercholesterolaemia OR hypercholesterolaemic OR hy-
percholesterolaemia OR high cholesterol levels OR elevated 
cholesterol OR hyperlipidaemia OR dyslipidaemia). We used 
the Medical Subject Headings database to define synonyms 
for the primary search terms, e.g. (ETC-1002: bempedoic 
acid OR ESP55016), to increase the sensitivity of our search 
results. Two authors independently screened the titles and 
abstracts of the retrieved citations and full-text evaluation 
was subsequently performed. Discrepancies were resolved 
by discussion between authors. 
Data extraction
Two authors extracted the data independently using an on-
line standardised extraction form prepared in MS Excel. The 
extracted data included the following: (1) characteristics of 
study design, (2) baseline data of enrolled patients, (3) ROB 
domains, and (4) study outcomes. Dichotomous data were 
extracted as events and total number of patients within study 
groups, while continuous data were extracted as means, 
standard deviations, and numbers of patients within study 
groups. Any discrepancies were discussed by the authors until 
consensus was reached.
Quality assessment
The ROB in the eligible studies was assessed using the 
Cochrane Collaboration’s tool for ROB assessment in 
RCTs. The following domains were considered: generation of 
the allocation sequence, allocation concealment, blinding of 
participants, masking of outcome assessors, selective outcome 
reporting, incomplete follow-up, and other potential sources 
of bias. Following ROB assessment, we employed the Grading 
of Recommendations Assessment, Development, and Evalua-
tion (GRADE) approach at the outcome level [19]. Based on 
the GRADE approach, quality of the outcome evidence in 
the studies was labelled as very low, low, moderate, or high. 
Five domains were evaluated to grade the studies: (1) ROB, 
(2) generalisability of results, (3) consistency of results, 
(4) precision of data, and (5) risk of publication bias.
The quality of evidence was specifically determined by 
the study design (a randomised trial was graded “high,” an 
observational study was graded “low,” and any other evidence 
was graded “very low”). GRADE was lower if there were seri-
ous or very serious concerns with regard to the study quality, 
inconsistency, uncertainty about directness, sparse/imprecise 
data, or reporting bias. GRADE was higher when the evidence 
of association was strong or very strong, evidence of dose 
response gradient was reported, or plausible confounders 
would have reduced the reported effect.
Statistical analysis
Dichotomous data were pooled as odds ratio (OR) using the 
Mantel-Haenszel method. Continuous data were pooled as 
mean difference (MD) using the inverse-variance method. 
The missing standard deviations were calculated from the 
standard error or 95% confidence interval (CI) according to 
the Cochrane handbook for systematic review of interven-
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tions [20]. We used the Review Manager (RevMan version 
5.3 for windows) to conduct meta-analyses and generate the 
forest plots.
Assessment of heterogeneity
Heterogeneity was assessed by visual inspection of the forest 
plots and measured by I-square and c2 tests. We assessed and 
interpreted heterogeneity according to the recommendations 
of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Chapter 9) [20]. When significant heterogeneity was 
present (c2, p < 0.1), we performed the analysis under the 
random effects model. Otherwise, the fixed effects model 
was adopted. To identify the reason for the heterogeneity, we 
performed sensitivity analysis using the leave-one-out method.
Publication bias
According to Egger et al. [21], publication bias assessment is not 
reliable for less than 10 pooled studies per outcome. There-
fore, in the present study, we could not assess the existence 
of publication bias by Egger’s test for funnel plot asymmetry.
RESULTS
Summary and quality of the included studies
Database searching yielded 59 unique citations. After title and 
abstract screening, 13 full-text articles were left for further 
scrutiny. Of these, five articles were eligible for our review: 
four of them compared ETC-1002 to placebo and were eligible 
for meta-analysis [15–18]. The fifth article was a phase IIb trial 
that compared a range of doses of ETC-1002 to ezetimibe 
(EZE) alone and their combination (Fig. 1) [22]. The list of 
excluded studies and reasons for exclusion are illustrated in 
Supplementary Figure 3 (see journal website). The summary 
of the included studies and the baseline characteristics of the 
enrolled patients are presented in Table 1. 
The ROB in the included studies was assessed using the 
Cochrane ROB assessment tool (Suppl. Fig. 4 — see journal 
website). Independent evaluation of all pooled studies showed 
low ROB in terms of random sequence generation and selective 
outcome reporting. However, the ROB in allocation conceal-
ment was generally unclear. On the outcome level, all assessed 
outcomes in the included studies had a low risk of performance 
and detection bias. However, in two studies more than 10% of 
patients withdrew from the study due to adverse events, creat-
ing a high risk of attrition bias in all assessed outcomes [15, 18].
Outcomes
Efficacy
The overall mean difference favoured ETC-1002 over placebo 
in terms of percentage change from baseline in LDL-C level 
(MD –26.58, 95% CI –35.50 to –17.66, p < 0.0001, moderate 
certainty), non-HDL-C level (MD –21.54, 95% CI –28.48 to 
–14.6, p < 0.00001, moderate certainty), apolipoprotein-B 
level (MD –15.97, 95% CI –19.36 to –12.57, p < 0.0001, 
high certainty), LDL particle number (MD –18.75, 95% CI 
–23.26 to –14.24, p < 0.0001, moderate certainty), HDL 
particle number (MD 6.07, 95% CI 2.60–9.54, p = 0.0006, 
moderate certainty), and total cholesterol level (MD –17.2, 
95% CI –22.62 to –11.61, p < 0.00001, high certainty; Fig. 2).




Table 1. The summary of the included studies and baseline characteristics of patients
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men and women aged 
18–80 years with a BMI of 
18–45 kg/m2 who were on 
stable statin therapy, fasting, 
calculated LDL-C levels from 
115 to 220 mg/dL and a fasting 
TG level of ≤ 400 mg/dL after 
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Data are shown as mean ± standard deviation or number (percentage); BMI — body mass index; DBP — diastolic blood pressure; ETZ — ezetimibe; ETC-1002 —  
Education Programme Adult Treatment Panel III; SBP — systolic blood pressure; TC — total cholesterol; TG — triglycerides; VLDL — very low-density lipoprotein
On the other hand, our analysis showed no significant 
differences between ETC-1002 and placebo in terms of 
percentage changes from baseline in triglyceride levels (MD 
5.23, 95% CI –16.45 to 27.01, p = 0.64, moderate certainty), 
HDL-C level (MD –1.29, 95% CI –4.19 to 1.61, p = 0.38, high 
certainty), apolipoprotein-A1 level (MD 0.17, 95% CI –4.04 to 
4.38, p = 0.94, moderate certainty), lipoprotein(a) level 
(MD 0, 95% CI –13.74 to 13.74, p = 1, very low certainty), 
free fatty acids (MD –5.0, 95% CI –30.19 to 20.19, p = 0.7, 
very low certainty), and very low-density lipoprotein (VLDL) 
cholesterol particle number (MD –10.27, 95% CI –31.40 to 
10.86, p = 0.34, very low certainty) (Fig. 3). The reasons for 
the downgrading of evidence quality in the last three param-
eters included imprecision and uncertainty about directness.
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A1 and B, TG
bempedoic acid; HDL-C — high-density lipoprotein-cholesterol; LDL-C — low-density lipoprotein-cholesterol; NA — not applicable; NCEP ATP III — National Cholesterol 
cholesterol. Conversion factors to SI units: are as fallows: for TC, LDL-C, and HDL-C (in mg/dL) — 0.02586; for TG (in mg/dL) — 0.01129.
Significant heterogeneity was observed in only four out-
comes (LDL-C, non-HDL-C, total cholesterol, and triglyceride 
levels), and their analysis was conducted under the random 
effects model. Sensitivity analysis was possible in the first 
three outcomes in which heterogeneity was best resolved 
by removing the study by Gutierrez et al. 2014 [18], and 
the effect estimate remained significant in all four outcomes. 
Safety
ETC-1002 did not increase the risk of all adverse events (OR 
0.58, 95% CI 0.37–0.91, p = 0.02) or arthralgia (OR 0.32, 
95% CI 0.13–0.81, p = 0.02) compared to placebo. Fur-
thermore, we found no significant differences between both 
groups in the rate of serious adverse events (OR 0.35, 95% CI 




0.76, 95% CI 0.43–1.34, p = 0.34), adverse events leading 
to discontinuation (OR 0.57, 95% CI 0.23–1.46, p = 0.24), 
headache (OR 1.36, 95% CI 0.63–2.96, p = 0.43), urinary 
tract infection (OR 1.77, 95% CI 0.53–5.87, p = 0.35), and 
myalgia (OR 1.09, 95% CI 0.30–3.89, p = 0.9) (Fig. 4). All 
analyses of adverse effects had high certainty except for serious 
adverse events and adverse events leading to discontinuation 
(moderate certainty).
In a phase IIb randomised controlled trial [22], Thompson 
et al. [22] showed that ETC-1002 alone is more effective than 
EZE alone in reducing LDL-C levels. Both 120 mg and 180 mg 
doses of ETC-1002 were superior to EZE 10 mg dose in reducing 
LDL-C levels (–27.5 ± 1.3 vs. –30.1 ± 1.3 vs. –21.1 ± 1.3 for 
ETC-1002 120 mg, ETC-1002 180 mg and EZE 10 mg, re-
spectively). The combination of ETC-1002 and EZE was much 
more effective (–43.1 ± 2.6 vs. –47.7 ± 2.8 vs. –21.1 ± 1.3 
for ETC-1002 120 mg plus EZE 10 mg, ETC-1002 180 mg 
plus EZE 10 mg, and EZE 10 mg monotherapy, respectively). 
The analysis of LDL particle number, apolipoprotein-B, total 
cholesterol, non–HDL-C, and triglycerides levels favoured 
both ETC-1002 monotherapy and ETC-1002 plus EZE com-
bination over EZE alone.
DISCUSSION
In this systematic review and meta-analysis, we investigated 
the safety and efficacy of ETC-1002, a novel LDL-C lowering 
agent. A total of 625 hypercholesterolaemic patients were 
classified into either the ETC-1002 group (487 patients) or 
the placebo group (138 patients). Analysis of data extracted 
from four studies [15–18] showed that the overall MD of 
decreasing LDL-C, non–HDL-C, apolipoprotein-B, and total 
cholesterol levels as well as LDL particle number favoured 
Figure 2. Forest plots of the comparison between ETC-1002 and placebo in terms of mean differences in low-density lipoprotein 
cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non–HDL-C), apolipoprotein-B, LDL particle number, HDL particle 
number, and total cholesterol
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ETC-1002 over placebo. With regard to safety, there was no 
significant difference between placebo and ETC-1002 in terms 
of serious adverse events, treatment-related events, adverse 
events that led to discontinuation, headache, urinary tract 
infection, or myalgia.
Two studies included patients who were statin-intolerant 
due to muscular adverse events [17, 22]. In the study of 
Thompson et al. [22], the investigators compared two doses 
of ETC-1002 (120 and 180 mg) alone or combined with 
EZE 10 mg vs. EZE monotherapy in patients with hypercho-
lesterolaemia for lowering of LDL-C levels. It was the first 
study to compare ETC-1002 and other statin-alternative 
medications. The authors concluded that ETC-1002 with 
or without EZE may be useful and effective in patients with 
hypercholesterolaemia. Therefore, ETC-1002 may be useful 
for patients who are unable to tolerate statins because of 
muscle side effects.
Significant statistical heterogeneity was recorded in four 
outcomes (LDL-C, non-HDL-C, total cholesterol, and triglyc-
eride levels) and it was resolved upon excluding the study by 
Gutierrez et al. [18]. A possible reason for the heterogeneity 
caused by including this study in the analysis was the dif-
ference in baseline variables of the patients, compared to 
other studies. For example, this study only included diabetic 
patients, and the mean baseline total cholesterol, LDL-C, and 
HDL-C values in these patients were markedly lower than in 
their counterparts included in other studies. 
A pharmacokinetics study of ETC-1002 showed that this 
agent is rapidly absorbed from the small intestine. Moreover, 
it has cell surface receptors through which it enters the liver 
[23]. Chemically, ETC-1002 is a dicarboxylic acid derivative. 
It has two mechanisms of action: it inhibits hepatic ATP citrate 
lyase (ACL) and activates adenosine monophosphate-activated 
protein kinase (AMPK) [14]. Through these mechanisms, 
ETC-1002 exerts its effects on fatty acid and cholesterol me-
tabolism. ETC-1002 rapidly reduces acetyl coenzyme A (CoA) 
levels and induces the uptake of LDL particles by the liver, 
which leads to reduced blood LDL-C levels [23]. 
ETC-1002 has the potential to regulate metabolic im-
balance in both the lipid and carbohydrate metabolic path-
Figure 3. Forest plots of the comparison between ETC-1002 and placebo in terms of mean differences in triglycerides, high-
-density lipoprotein cholesterol (HDL-C), apolipoprotein-A1, lipoprotein(a), free fatty acids, and very low-density lipoprotein 




Figure 4. Forest plots of the comparison between ETC-1002 and placebo in terms of odds ratio of all adverse events, serious 
adverse events (AEs), treatment-related AEs, AEs that led to discontinuation, headache, urinary tract infection (UTI), myalgia,  
and arthralgia
www.kardiologiapolska.pl
Xiaolin Wang et al.
214
ways. In addition, it inhibits sterol and fatty acid synthesis, 
increases mitochondrial long-chain fatty acid oxidation, and 
improves glucose metabolism [24]. Because ETC-1002 targets 
different enzymes in the cholesterol synthesis cascade, the 
end result is overall reduction in cholesterol synthesis. The 
decreased cholesterol synthesis leads to upregulation of LDL 
receptors and subsequent reduction in the circulating levels 
of LDL-C (which is similar to the mechanism of statins). 
On the other hand, activation of AMPK leads to inhibitory 
phosphorylation of acetyl-CoA carboxylase and HMG-CoA 
reductase, which in turn leads to decreased blood glucose, 
lipid, and body weight [23].
Strengths and limitations
In this study, we performed a comprehensive search of five 
major databases to retrieve all relevant studies. The low risk 
of bias in most domains on the Cochrane ROB tool adds to 
the strength of our findings. We also performed a GRADE 
assessment to evaluate the certainty of evidence. This assess-
ment showed an acceptable level of reliability for our findings 
because most outcomes had good levels of certainty (ranging 
from moderate to high). However, in three outcomes, the 
evidence certainty was very low (lipoprotein[a], free fatty ac-
ids, and VLDL cholesterol particle number), and the reasons 
for evidence certainty downgrade included imprecision and 
uncertainty about directness. Future studies should focus on 
these parameters. 
One of the limitations of our study was the difference in 
baseline characteristics of the patients included in the studies 
(age, diabetes, and other cardiovascular risk factors). Moreo-
ver, the included studies used different doses and durations 
of treatment with ETC-1002 (doses ranged from 40 to 240 mg 
and duration of therapy ranged from six to 12 weeks). The 
80 and 120 mg doses were investigated in most of the stud-
ies; therefore, they are better candidates for future research. 
Ballantyne et al. [15] administered ETC-1002 at 40, 80, 
and 120 mg for 12 weeks, while Ballantyne et al. [16] used 
ETC-1002 120 and 180 mg for the same period. Thompson 
et al. [17] started with ETC-1002 at 60 mg then increased 
the dose to 120, 180, and 240 mg for eight weeks, while in 
a study by Thompson et al. [22], patients were randomised to 
12-week treatment with ETC-1002 120 or 180 mg. Addition-
ally, our search was limited to articles published in English, 
therefore, owing to the small number of included studies, we 
could not assess the risk of publication bias. Another common 
limitation related to the meta-analysis design of the study is 
that the results are limited by the data presented in the in-
cluded studies. Therefore, in this study, we could not analyse 
the impact of ETC-1002 on clinically relevant outcomes such 
as blood pressure or ischaemic manifestations.
Future research recommendations
Future studies should directly compare ETC-1002 to statins in 
terms of efficacy to prove non-inferiority. The impact of ETC-
1002 treatment on clinical outcomes and complications of 
hypercholesterolaemia, such as coronary and peripheral artery 
disease, should be investigated in future trials. Moreover, basic 
scientific and translational research should be encouraged 
to identify new targets of cholesterol-lowering therapy and 
develop more drugs from phytochemical and pharmaceutical 
agents [25, 26].
In conclusion, ETC-1002 is a safe and effective lipid-low-
ering agent in hypercholesterolaemic patients and may be 
a good treatment alternative for patients with statin intoler-
ance. Moreover, the combination of ETC-1002 and EZE could 
offer better lipid-lowering effects than EZE alone. Except for 
a few outcomes that should be further investigated (such as 
free fatty acids and VLDL cholesterol particle number), the 
evidence certainty for most of the analysed results was moder-
ate to high. Future studies should make head-to-head com-
parisons between ETC-1002 and statins and investigate the 
benefits of replacing or supplementing statins with ETC-1002.
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WHAT IS NEW?
Statins are the current gold standard in the treatment for hypercholesterolaemia. However, owing to their myopathic 
adverse effects, safer alternatives are being investigated. Bempedoic acid (ETC-1002) is a novel low-density lipoprotein 
cholesterol (LDL-C)-lowering agent, currently under trial in hypercholesterolaemic patients. Using statistical pooling of 
randomised controlled trials, we summarised the safety and efficacy outcomes of ETC-1002 use in these patients. ETC-1002  
was effective in improving the levels of LDL-C, non–high-density lipoprotein cholesterol, and apolipoprotein-B  
as compared to placebo. When compared to ezetimibe, ETC-1002 was superior in reducing LDL-C levels. Moreover, 
ETC-1002 was not associated with increased risk of all adverse events, including arthralgia, myalgia, headache, and 
urinary tract infections, compared to placebo. In summary, ETC-1002 is a safe and effective cholesterol-lowering agent 
and may be a suitable alternative in statin-intolerant patients.
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